FAPI诊疗一体化当前研究主题:文献计量学分析
该文献计量学分析检索PubMed至2022年5月31日,纳入294篇FAPI显像与放射性核素治疗原创研究,其中209篇(71%)为病例报告/系列、85篇(29%)为队列研究;68%聚焦恶性肿瘤,42%聚焦良性疾病,16篇(5%)涉及放射性核素治疗。作者结论认为FAPI研究正快速扩展,但需从低证据级别病例报告转向前瞻性设计研究。
要点
- 共纳入294篇FAPI原创研究,71%为病例报告/系列,29%为队列研究。
- 68%研究聚焦恶性肿瘤,胃肠癌、肝胆胰癌、混合癌/转移、肺癌、肉瘤、头颈癌、乳腺癌最常见。
- 16篇(5%)涉及放射性核素治疗,初步报告毒性可接受、肿瘤活性滞留及疾病控制提示。
核心结论
- FAPI研究正从恶性肿瘤和良性疾病的诊断研究快速扩展至首批挽救性放射性核素治疗报告。
- 作者认为研究活动需从低证据级别的病例报告和系列转向同质患者组的前瞻性设计研究,以提供FAPI诊疗一体化在何种临床情境下具有附加价值的证据。
研究设计与样本
- 文献计量学分析,通过PubMed检索截至2022年5月31日所有MEDLINE收录的FAPI显像与放射性核素治疗文献。
- 共识别294篇原创研究,包括209篇(71%)病例报告/系列和85篇(29%)队列研究。
- 建立在线文献数据库并对相关研究分配层级主题标签,采用频率分析评估首作者来源国、发表期刊、研究设计、显像技术与放射性药物、组织病理学相关性、癌症类型及良性疾病/摄取类型等特征分布。
主要发现
- 多数研究聚焦显像主题,主要比较FAPI-PET/CT与2-[18F]FDG-PET/CT、解剖影像和/或组织病理学结果的摄取。
- 68%的研究聚焦恶性肿瘤,最常见的癌症类型为胃肠癌、肝胆胰癌、混合癌/转移、肺癌、肉瘤、头颈癌和乳腺癌。
- 42%的研究聚焦良性疾病类别,最常见为心血管、肌肉骨骼、肝胆胰、头颈和IgG4相关疾病。
- 16/294(5%)的研究聚焦放射性核素治疗,初步报告显示毒性特征可接受、肿瘤活性滞留及疾病控制提示。
关键数值与推荐
- 294篇原创研究中209篇(71%)为病例报告/系列,85篇(29%)为队列研究。
- 68%的研究聚焦恶性肿瘤,42%的研究聚焦良性疾病。
- 16/294(5%)的研究聚焦放射性核素治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The study aimed to provide a comprehensive bibliometric overview of the current scientific publications on fibroblast activation protein inhibitor (FAPI) positron emission tomography imaging and radionuclide therapy. METHODS: A PubMed search was performed to identify all MEDLINE-indexed publications on FAPI imaging and radionuclide therapy. The last update was performed on 31 May 2022. An online database of this literature was created, and hierarchical topic-related tags were subsequently assigned to all relevant studies. Frequency analysis was used to evaluate the distribution of the following characteristics: first author's country of origin, journal of publication, study design, imaging techniques and radiopharmaceutical used, histopathological correlation, the type of cancer, and benign disease/uptake types evaluated. RESULTS: A total of 294 relevant publications on original studies were identified, consisting of 209 (71%) case reports/series and 85 cohort studies (29%). The majority of studies focused on imaging topics, predominantly comparing uptake on FAPI-PET/CT with 2-[18F]FDG-PET/CT, anatomical imaging, and/or histopathology results. 68% of studies focused on malignancies, with gastro-intestinal cancer, hepato-pancreato-biliary cancer, mixed cancers/metastases, lung cancer, sarcoma, head and neck cancer, and breast cancer being the most frequently reported. 42% of studies focused on benign disease categories, with cardiovascular, musculoskeletal, HPB, head and neck, and IgG4-related disease as most common categories. 16/294 (5%) studies focused on radionuclide therapy, with preliminary reports of acceptable toxicity profiles, tumour activity retention, and suggestion of disease control. CONCLUSION: FAPI research is rapidly expanding from diagnostic studies in malignancies and benign diseases to the first reports of salvage radionuclide therapy . The research activity needs to shift now from low-level-of-evidence case reports and series to prospectively designed studies in homogenous patient groups to provide evidence on how and in which clinical situations FAPI theranostics can be of added value to clinical care. We have provided an overview of current research topics to build upon.
引用
- van den Hoven AF, Keijsers RGM, Lam MGEH, et al. Current research topics in FAPI theranostics: a bibliometric analysis. Eur J Nucl Med Mol Imaging. 2022. PMID: 36437424. doi:10.1007/s00259-022-06052-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。